NCT01242774 - Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG

Panobinostat

Oral administration of panobinostat given 3 times a week (administered on weeks 2 and 3 of a 4 week cycle) in combination with induction chemotherapy (idarubicin and cytarabine.

Trial Locations (10)

29425

Medical University of South Carolina -Hollings Cancer Center MUSC/HCC (2), Charleston

30625

Novartis Investigative Site, Hanover

37007

Novartis Investigative Site, Salamanca

37212

Vanderbilt University Medical Center, Clinical Trials Center Vanderbilt 3, Nashville

43210

Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept.ofJamesCancerHospital, Columbus

89081

Novartis Investigative Site, Ulm

94304

Stanford University Medical Center Stanford U, Stanford

02115

Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr, Boston

01307

Novartis Investigative Site, Dresden

08025

Novartis Investigative Site, Barcelona